Since the dysregulation of USP14 has been implicated in multiple human cancers (Li H. et al., 2019; Sharma et al., 2020), USP14 inhibitors may be also applicable to treat other cancers with altered USP14 activity. This evidence concerns the gene USP14 and cancer.